

IN THE SPECIFICATION

Please amend the specification as follows:

Please replace the paragraph at page 10, lines 3-4, with the following:

FIG. 9 shows name and composition of ADIS AIDS DNA vaccines used in the present invention, wherein

Group 1: pTV,

Group 2: pTV-SIV/GE ("pTV-GE") + pTV-SIV/pol ("pTV-dpol"),

Group 3: pTV-SIV/GE ("pTV-GE") + pTV-SIV/pol ("pTV-dpol") + pTV-SIV/GE-GC ("pTV-GE-GC") + pTV-SIV/pol-IL-2 ("pTV-dpol-IL2"),

Group 4: pTV-SIV/GE ("pTV-GE") + pTV-SIV/pol ("pTV-dpol") priming and subunit vaccine boosting.

Please replace the paragraph at page 13, lines 15-20, with the following:

Each of the plasmids pTV-SIV/GE and pTV-SIV/pol was transformed to DH5 α cells and the transformed strains were deposited in the Korean Collection for Type Culture of Korea Research Institute of Bioscience and Biotechnology (KRIBB), at #52, Oun-dong, Yusong-ku, Taejeon 305-333, Republic of Korea, on Nov. 27, 1999 (Accession NO: KCTC 0702BP and KCTC 0703BP).

Please replace the paragraph at page 22, lines 3-11, with the following:

Each of the plasmids prepared in the Example 1 was dissolved to the concentration of 1 mg/ml in physiological saline (0.85 % NaCl). Into two rhesus monkeys (Group 4 2), the plasmids pTV-SIV/GE and pTV-SIV/pol were administered by intramuscular injection at a dose of 400 μ g, each, per head. For a control group (Group 2 1) comprising three rhesus monkeys, a vector DNA carrying no SIV genes (pTV) was used at a dose of 800 μ g in the same injection manner.